Cellectar Biosciences Inc (CLRB.OQ)
CLRB.OQ on NASDAQ Stock Exchange Capital Market
2.70USD
21 Sep 2018
2.70USD
21 Sep 2018
Change (% chg)
$-0.06 (-2.17%)
$-0.06 (-2.17%)
Prev Close
$2.76
$2.76
Open
$2.76
$2.76
Day's High
$2.79
$2.79
Day's Low
$2.63
$2.63
Volume
24,127
24,127
Avg. Vol
34,406
34,406
52-wk High
$20.40
$20.40
52-wk Low
$2.03
$2.03
About
Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery... (more)
Overall
| Beta: | 1.02 |
| Market Cap(Mil.): | $23.88 |
| Shares Outstanding(Mil.): | 13.92 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| CLRB.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 30.93 | 32.76 |
| EPS (TTM): | -1.24 | -- | -- |
| ROI: | -103.68 | 15.07 | 14.61 |
| ROE: | -105.20 | 16.59 | 16.33 |
BRIEF-Cellectar Granted Orphan Drug Designation For CLR 131
* CELLECTAR GRANTED ORPHAN DRUG DESIGNATION FOR CLR 131 TO TREAT RHABDOMYOSARCOMA Source text for Eikon: Further company coverage:
BRIEF-Cellectar Biosciences Appoints Brian M. Posner As Chief Financial Officer
* CELLECTAR BIOSCIENCES APPOINTS BRIAN M. POSNER AS CHIEF FINANCIAL OFFICER
BRIEF-Cellectar Granted Seminal U.S. Patent For Phospholipid-Ether Analogs As Cancer-Targeting Drug Vehicles
* CELLECTAR GRANTED SEMINAL U.S. PATENT FOR PHOSPHOLIPID-ETHER ANALOGS AS CANCER-TARGETING DRUG VEHICLES Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)
Competitors
| Price | Chg | |
|---|---|---|
| Johnson & Johnson (JNJ.N) | $142.88 | +0.90 |
| Bayer AG (BAYGn.DE) | €76.52 | +0.70 |
| Bayer AG (BAYE.F) | -- | -- |
| Sanofi SA (SASY.PA) | €74.50 | -0.17 |
| Roche Holding Ltd. (ROG.S) | CHF235.15 | +0.10 |
| Roche Holding Ltd. (RO.S) | CHF235.40 | -1.20 |
| Bristol-Myers Squibb Co (BMY.N) | $62.25 | +0.50 |
| Bristol-Myers Squibb Co (BMYMP.PK) | $1,034.45 | -- |
| Pfizer Inc. (PFE.N) | $44.06 | +0.31 |
| Spectrum Pharmaceuticals, Inc. (SPPI.OQ) | $21.36 | -0.16 |
Estimates